ArticleTransboundary and emerging diseases2026
Extended-Spectrum Beta-Lactamase (ESBL)-Producing E. coli in Livestock and Free-Roaming Wildlife: A Combined Phenotyping-Whole-Genome Sequencing One Health Approach.
Article in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From clinics to sewers: leveraging environmental surveillance and whole genome sequencing to inform transmission of ESBL-Applied and environmental microbiology · 2026Article
- Extended-Spectrum Beta-Lactamase (ESBL)-Producing E. coli in Livestock and Free-Roaming Wildlife: A Combined Phenotyping-Whole-Genome Sequencing One Health Approach.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Antimicrobial resistance (AMR) in Enterobacterales, particularly extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-Ec), poses a significant public health concern. Widespread antimicrobial use exerts selection pressure, driving the persistence and spread of resistant bacteria in diverse environments. While ESBL-Ec is well-documented in clinical and agricultural settings, its presence in animal reservoirs remains poorly understood. This study assessed the prevalence, AMR profiles, and genetic diversity of ESBL-Ec in Swiss dairy cattle and wildlife. Between 2021 and 2023, 775 samples were analyzed, including rectal swab samples from dairy cows (n = 475) and fecal or cloacal swab samples from wildlife (n = 300). ESBL-Ec was detected in 3/475 (0.6%, 95% confidence interval [CI] 0.2%-1.8%) of dairy cattle and 15/300 (5%, 95% CI 3.1%-8.1%) wildlife samples, with higher prevalence in birds (6/99, 6.1%, 95% CI 2.8%-12.6%) than mammals (9/200, 4.5%, 95% CI 2.4%-8.3%). Whole-genome sequencing (WGS) of 54 ESBL-Ec isolates identified 28 sequence types (STs) with no overlap between livestock and wildlife, suggesting distinct evolutionary trajectories. Phenotypic testing revealed resistance beyond beta-lactams, notably against aminoglycosides, tetracyclines, and sulfonamides, whereas all isolates remained susceptible to tigecycline and meropenem. Multidrug resistance (MDR) was prevalent (89%), with bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.